scholarly journals Sertoli-Leydig Cell Tumor (SLCT) of the Ovary - A Case Report

2019 ◽  
Vol 13 (2) ◽  
pp. 104-107
Author(s):  
Mst Moonmoon Begum ◽  
Ferdousi Sultana
Keyword(s):  
Leydig Cell ◽  
Early Stage ◽  
Strong Association ◽  
Leydig Cell Tumor ◽  
Cell Tumor ◽  
Primary Amenorrhea ◽  
Suspected Case ◽  
Early Stage Disease ◽  
Stage Disease ◽  
Age Range

Sertoli-Leydig Cell Tumor (SLCT) is an extremely rare and distinctive sex cord-stromal tumor. Ovarian sex cordstromal tumors are infrequent tumors that differ from the more frequent epithelial neoplasm and have strong association with hormone-mediated syndromes, presentation in a wide age range, and the diagnosis is usually at early-stage disease with a good outcome. SLCT typically present with pelvic or abdominal pain and tenderness, mass, and or abnormal menstruation, and with hormonal activity reported predominantly after menarche. We report a case of 18-year-old unmarried female presented with severe pain and lump in the lower abdomen and also a case of primary amenorrhea with normal secondary sex characters. She was a suspected case of twisted ovarian tumor on USG and underwent laparotomy followed by total excision of the lump and histopathology report revealed Sertoli- Leydig Cell Tumor. Though it is a rare tumor, the possibility of Sertoli-Leydig Cell Tumor in a young woman should be kept in mind. Faridpur Med. Coll. J. Jul 2018;13(2): 104-107

scholarly journals Sertoli-Leydig Cell Tumor (SLCT) of the Ovary - A Case Report

2020 ◽  
Vol 32 (2) ◽  
pp. 117-120
Author(s):  
Mst Moonmoon Begum ◽  
Ferdousi Sultana
Keyword(s):  
Leydig Cell ◽  
Ovarian Tumor ◽  
Early Stage ◽  
Leydig Cell Tumor ◽  
Cell Tumor ◽  
Stromal Tumor ◽  
Primary Amenorrhea ◽  
Suspected Case ◽  
Early Stage Disease ◽  
Sex Cord Stromal Tumor

Sertoli-Leydig Cell Tumor (SLCT) is an extremely rare and distinctive sex cord-stromal tumor. Ovarian sex cord-stromal tumors are infrequent tumors that differ from the more frequent epithelial neoplasm and have strong association with hormone-mediated syndromes, presentation in a wide age range, and the diagnosis is usually at early-stage disease with a good outcome. SLCT typically present with pelvic or abdominal pain and tenderness, mass, and or abnormal menstruation, and with hormonal activity reported predominantly after menarche. We report a case of 18-year-old unmarried female presented with severe pain and lump in the lower abdomen. She was a case of primary amenorrhea with normal secondary sex characters. She was a suspected case of twisted ovarian tumor on USG and underwent laparotomy followed by total excision of the lump and histopathology report revealed Sertoli-Leydig Cell Tumor. Though it is a rare tumor, the possibility of Sertoli-Leydig Cell Tumor in a young woman should be kept in mind. Key Words: Ovarian tumor, Sclerosing stromal tumor, sex cord-stromal tumor, Sertoli- Leydig Cell Tumor. Bangladesh J Obstet Gynaecol, 2017; Vol. 32(2) : 117-120

scholarly journals Virilising ovarian tumors: a single-center experience

2018 ◽  
Vol 7 (12) ◽  
pp. 1362-1369
Author(s):  
Manjeetkaur Sehemby ◽  
Prachi Bansal ◽  
Vijaya Sarathi ◽  
Ashwini Kolhe ◽  
Kanchan Kothari ◽  
...  
Keyword(s):  
Leydig Cell ◽  
Serum Testosterone ◽  
Leydig Cell Tumor ◽  
Cell Tumor ◽  
Ovarian Tumors ◽  
Reproductive Age ◽  
Primary Amenorrhea ◽  
Total Testosterone ◽  
Western India ◽  
Duration Of Symptoms

Literature on virilising ovarian tumors (VOTs) is limited to case reports and series reporting single pathological type. We have analyzed the clinical, hormonal, radiological, histological, management and outcome data of VOT. This retrospective study was conducted at a tertiary health care center from Western India. Consecutive patients with VOT presenting to our endocrine center between 2002 and 2017 were included. Our study included 13 patients of VOT. Out of 13 patients, two were postmenopausal. All patients in the reproductive age group had secondary amenorrhea except one who presented with primary amenorrhea. Modified F and G score (mFG) at presentation was 24 ± 4.3 and all patients had severe hirsutism (mFG ≥15). Change in voice (n = 11) and clitoromegaly (n = 7) were the other most common virilising symptoms. Duration of symptoms varied from 4 to 48 months. Median serum total testosterone level at presentation was 5.6 ng/mL with severe hyperandrogenemia (serum testosterone ≥2 ng/mL) but unsuppressed gonadotropins in all patients. Transabdominal ultrasonography (TAS) detected VOT in all except one. Ten patients underwent unilateral salpingo-oophorectomy whereas three patients (peri- or postmenopausal) underwent total abdominal hysterectomy and bilateral salpingo-oophorectomy. Seven patients had Sertoli Leydig cell tumor, three had steroid cell tumor and two had Leydig cell tumor and one had miscellaneous sex cord stromal tumor. All patients had normalization of serum testosterone after tumor excision. In conclusion, VOTs present with severe hyperandrogenism and hyperandrogenemia. Sertoli Leydig cell tumor is the most common histological subtype. Surgery is the treatment of choice with good surgical outcome.

Hyperandrogenism caused by a leydig cell tumor of the ovary: A case report

2020 ◽  
Author(s):  
Fernando Mendonça ◽  
Selma Souto ◽  
Daniela Magalhães ◽  
Ana Sofia Fernandes ◽  
Ana Rita Coelho ◽  
...  
Keyword(s):  
Case Report ◽  
Leydig Cell ◽  
Leydig Cell Tumor ◽  
Cell Tumor

Novel approaches to improve prostate cancer diagnosis and management in early-stage disease

2012 ◽  
Vol 109 ◽  
pp. 1-7 ◽  
Author(s):  
Michael Marberger ◽  
Jelle Barentsz ◽  
Mark Emberton ◽  
Jonas Hugosson ◽  
Stacy Loeb ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Diagnosis ◽  
Early Stage ◽  
Early Stage Disease ◽  
Prostate Cancer Diagnosis ◽  
Diagnosis And Management ◽  
Stage Disease ◽  
Novel Approaches ◽  
Improve Prostate Cancer

scholarly journals Surgery in Small-Cell Lung Cancer

Cancers ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 390
Author(s):  
Nicola Martucci ◽  
Alessandro Morabito ◽  
Antonello La Rocca ◽  
Giuseppe De Luca ◽  
Rossella De Cecio ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Early Stage ◽  
Small Cell ◽  
Stage I ◽  
Phase Iii ◽  
Small Cell Lung ◽  
Early Stage Disease ◽  
Stage Disease

Small-cell lung cancer (SCLC) is one of the most aggressive tumors, with a rapid growth and early metastases. Approximately 5% of SCLC patients present with early-stage disease (T1,2 N0M0): these patients have a better prognosis, with a 5-year survival up to 50%. Two randomized phase III studies conducted in the 1960s and the 1980s reported negative results with surgery in SCLC patients with early-stage disease and, thereafter, surgery has been largely discouraged. Instead, several subsequent prospective studies have demonstrated the feasibility of a multimodality approach including surgery before or after chemotherapy and followed in most studies by thoracic radiotherapy, with a 5-year survival probability of 36–63% for patients with completely resected stage I SCLC. These results were substantially confirmed by retrospective studies and by large, population-based studies, conducted in the last 40 years, showing the benefit of surgery, particularly lobectomy, in selected patients with early-stage SCLC. On these bases, the International Guidelines recommend a surgical approach in selected stage I SCLC patients, after adequate staging: in these cases, lobectomy with mediastinal lymphadenectomy is considered the standard approach. In all cases, surgery can be offered only as part of a multimodal treatment, which includes chemotherapy with or without radiotherapy and after a proper multidisciplinary evaluation.

Sign in / Sign up

Export Citation Format

Share Document